Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study

Journal of the American College of Cardiology

Volumn 41, Issue 10, 2003, Pages 1721-1724

  Fuchs, Shmuel ^a   Satler, Lowell F ^a   Kornowski, Ran ^b   Okubagzi, Petros ^a   Weisz, Giora ^c   Baffour, Richard ^a   Waksman, Ron ^a   Weissman, Neil J ^a   Cerqueira, Manuel ^a   Leon, Martin B ^c   Epstein, Stephen E ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b RABIN MEDICAL CENTER   (Israel)

^c LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CATHETERIZATION; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; INFECTION; INSTRUMENTAL DELIVERY; MALE; MYOCARDITIS; PILOT STUDY; PRIORITY JOURNAL; SCAR FORMATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREADMILL EXERCISE;

EID: 0037564082     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00328-0     Document Type: Article

References (11)

1. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
2. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
3. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52.
4. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-32.
5. Kornowski R, Leon MB, Fuchs S, et al. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol 2000;35:1031-9.
6. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
7. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
8. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333-41.
9. Hamano K, Nishida M, Hirata K, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 2001;65:845-7.
10. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10.
11. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101:118-21.